Trademark: 77673768
Word
OXFORD BIOMEDICA
Status
Dead
Status Code
710
Status Date
Friday, January 5, 2018
Serial Number
77673768
Registration Number
3968293
Registration Date
Tuesday, May 31, 2011
Mark Type
4000
Filing Date
Thursday, February 19, 2009
Published for Opposition
Tuesday, March 15, 2011
Cancellation Date
Friday, January 5, 2018

Trademark Owner History
Oxford BioMedica plc - Original Registrant

Classifications
1 Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; polypeptides for in vitro research use, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific research use, cloning vehicles in the nature of plasmids, microbes and chemical reagents for DNA cloning for laboratory and scientific research use, chemicals for laboratory, scientific and biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research use, namely, in vitro and in vivo use
5 Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes; pre-filled vials for medical purposes and for pharmaceutical and biochemical preparations, for use in gene therapy and for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders
10 Instruments and apparatus for the administration of pharmaceutical, gene therapy and/or vaccine preparations and substances, namely, medical syringes and injectors for medical purposes
42 Scientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development for new products in the field of biotechnology, advisory services relating to gene therapy products and clinical trials, conducting clinical trials
44 Medical services; advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders and contraceptives
"OXFORD"
OXFORD BIO MEDICAL

Trademark Events
Jan 5, 2018
Cancelled Sec. 8 (6-Yr)
May 31, 2011
Registered-Principal Register
Mar 15, 2011
Official Gazette Publication Confirmation E-Mailed
Mar 15, 2011
Published For Opposition
Feb 8, 2011
Law Office Publication Review Completed
Jan 31, 2011
Approved For Pub - Principal Register
Jan 31, 2011
Examiner's Amendment Entered
Jan 31, 2011
Notification Of Examiners Amendment E-Mailed
Jan 31, 2011
Examiners Amendment E-Mailed
Jan 31, 2011
Examiners Amendment -Written
Jan 6, 2011
Teas/Email Correspondence Entered
Jan 6, 2011
Correspondence Received In Law Office
Jan 6, 2011
Assigned To Lie
Dec 9, 2010
Teas Response To Suspension Inquiry Received
Jun 14, 2010
Notification Of Inquiry As To Suspension E-Mailed
Jun 14, 2010
Inquiry To Suspension E-Mailed
Jun 14, 2010
Suspension Inquiry Written
Dec 11, 2009
Notification Of Letter Of Suspension E-Mailed
Dec 11, 2009
Letter Of Suspension E-Mailed
Dec 11, 2009
Suspension Letter Written
Dec 1, 2009
Notification Of Letter Of Suspension E-Mailed
Dec 1, 2009
Letter Of Suspension E-Mailed
Dec 1, 2009
Suspension Letter Written
Nov 20, 2009
Teas/Email Correspondence Entered
Nov 20, 2009
Correspondence Received In Law Office
Nov 20, 2009
Assigned To Lie
Nov 9, 2009
Teas Response To Office Action Received
May 11, 2009
Notification Of Non-Final Action E-Mailed
May 11, 2009
Non-Final Action E-Mailed
May 11, 2009
Non-Final Action Written
May 11, 2009
Assigned To Examiner
Feb 24, 2009
Notice Of Pseudo Mark Mailed
Feb 23, 2009
New Application Office Supplied Data Entered In Tram
Feb 23, 2009
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24